Literature DB >> 12830913

Development and validation of an improved method for the analysis of vancomycin by liquid chromatography selectivity of reversed-phase columns towards vancomycin components.

José Diana1, Dora Visky, Eugène Roets, Jos Hoogmartens.   

Abstract

The current method prescribed in official monographs for the purity control of vancomycin is inappropriate in that several components are not separated from each other and other components are coeluted with the main component vancomycin B. The method uses an ODS column at pH 3.2. In this study, several changes were introduced in order to improve the separation. The optimization of the separation method at low pH indicated that pH 1.7 was optimum and that the use of dioxane as organic modifier drastically improved the separation. These conditions were used to test a set of more than 40 reversed-phase columns for their selectivity towards vancomycin components. The selection of the most suitable columns was performed by means of principal component analysis. Most of these columns did not allow the separation of didechlorovancomycin from monodechlorovancomycin 1. It was found that neutral to slightly alkaline mobile phases allowed better separation. Further optimization of the separation method and a robustness study were performed by means of experimental design. This optimization indicated that pH 7.7 was optimum and gradient elution was also used to effect complete analysis. The final method uses a Kromasil column and the mobile phase comprises dioxane, water and ammonium formate solution pH 7.7. The separation of monodechlorovancomycin 2 and of some unknown impurities from the main component vancomycin B is described for the first time. The method shows good repeatability, linearity and sensitivity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12830913     DOI: 10.1016/s0021-9673(03)00535-1

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  3 in total

1.  Quality assessment of U.S. marketplace vancomycin for injection products using high-resolution liquid chromatography-mass spectrometry and potency assays.

Authors:  Michael E Hadwiger; Cynthia D Sommers; Daniel J Mans; Vikram Patel; Michael T Boyne
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

2.  Three structurally-related impurities in norvancomycin drug substance.

Authors:  Zhibo Jiang; Xuan Lei; Minghua Chen; Bingya Jiang; Linzhuan Wu; Xuexia Zhang; Zhihui Zheng; Xinxin Hu; Xuefu You; Shuyi Si; Lifei Wang; Bin Hong
Journal:  J Antibiot (Tokyo)       Date:  2016-10-05       Impact factor: 2.649

3.  Development and validation of an HPLC method for the determination of vancomycin in human plasma and its comparison with an immunoassay (PETINIA).

Authors:  Muhammad Usman; Georg Hempel
Journal:  Springerplus       Date:  2016-02-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.